A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-348(6)

NCT ID: NCT06112678

Last Updated: 2024-03-26

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 63 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-01-04
• Study Completion Date: 2024-03-18

Brief Summary

A phase I clinical trial to evaluate the tolerability and the pharmacokinetics of CKD-348(6).

Conditions

Hypertension; Dyslipidemias

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Sequence 1

Period 1: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition Period 2: CKD-348(6) - A single oral dose of 1 tablet under fasting condition Period 3: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition Period 4: CKD-348(6) - A single oral dose of 1 tablet under fasting condition

Group Type: EXPERIMENTAL

CKD-348(6)

Intervention Type: DRUG

QD, PO

CKD-828, D097, D337

Intervention Type: DRUG

QD, PO

Sequence 2

Period 1: CKD-348(6) - A single oral dose of 1 tablet under fasting condition Period 2: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition Period 3: CKD-348(6) - A single oral dose of 1 tablet under fasting condition Period 4: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition

Group Type: EXPERIMENTAL

CKD-348(6)

Intervention Type: DRUG

QD, PO

CKD-828, D097, D337

Intervention Type: DRUG

QD, PO

Interventions

CKD-348(6)

QD, PO

Intervention Type: DRUG

CKD-828, D097, D337

QD, PO

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Healthy adult volunteers aged ≥ 19 years.

2. Body weight ≥55kg with calculated body mass index (BMI) of 18 to 30 kg/m2

3. Those who meet the blood pressure criteria during screening tests:

• Systolic Blood Pressure: 90 to 139 mmHg
• Diastolic Blood Pressure: 60 to 89 mmHg

4. Those who have no congenital diseases or chronic diseases and have no abnormal symptoms or findings.

5. Those who are eligible for clinical trials based on laboratory (hematology, blood chemistry, serology, urology) and ECG results at screening.

6. Those who agree to contraception during the participation of clinical trial.

7. Those who voluntarily decide to participate and agree to comply with the cautions after fully understand the detailed description of this clinical trial.

Exclusion Criteria

1. Those who received investigational products or participated in bioequivalence tests within 6 months before the first administration of clinical trial drugs.

2. Those who take barbiturate and any related drugs which may cause induction or inhibition of drug metabolism within 1 month and those who take drug could affect to clinical trial within 10 days before the first administration of investigational products.

3. Those who donated whole blood or apheresis within 8 weeks or 4 weeks respectfully, or received blood transfusion within a month.

4. Those who have a history of gastrointestinal surgery except simple appendectomy and hernia surgery.

5. Those who exceed an alcohol and cigarette consumption criteria write below within 1 month before the first administration of investigational products.

• Alcohol: Man - 21 glasses/week, Woman - 14 glasses/week (1glass: Soju 50mL, Wine 30mL, or beer 250mL)
• Smoking: 20 cigarettes/day

6. Those who have any history of diabetic mellitus, nephropathy, biliary obstruction, shock, angioedema, cardiac insufficiency, dihydropyridine sensitivity, unstable angina, hypothyroidism and hypersensitive to Sunset yellow FCF.

7. Those who have genetic problems such as galactose intolerance, Lapp lactose deficiency or glucose-galactose malabsorption.

8. Those who are deemed insufficient to participate in this clinical trial by investigators.

9. Woman who are pregnant or breastfeeding.

• Minimum Eligible Age: 19 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Chong Kun Dang Pharmaceutical

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Seung-Hyun Kang, M.D., Ph.D

Role: PRINCIPAL_INVESTIGATOR

H Plus Yangji Hospital

Locations

H plus Yangji hospital

Seoul, , South Korea

Countries

South Korea

Other Identifiers

A86_13BE2314

Identifier Type: -

Identifier Source: org_study_id